NewEdge Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

NewEdge Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75	Hold	8	–	–	﹤0.01%	4147
2026 Q1	$75	Hold	8	–	–	﹤0.01%	4093
2025 Q4	$65	Hold	8	–	–	﹤0.01%	4165
2025 Q3	$101	Hold	8	–	–	﹤0.01%	4032
2025 Q2	$55	Sell	8 -1	-11%	-$7	﹤0.01%	3927
2025 Q1	$47	Buy	9 +1	+13%	+$9	﹤0.01%	3855
2024 Q4	$94	Sell	8 -6,568	-100%	-$110K	﹤0.01%	3784
2024 Q3	$136K	Buy	6,576 +8	+0.1%	+$409	﹤0.01%	2102
2024 Q2	$297K	Buy	6,568 +6,560	+82,000%	+$276K	﹤0.01%	1725
2024 Q1	$314	Hold	8	–	–	﹤0.01%	3636
2023 Q4	$48	Hold	8	–	–	﹤0.01%	3671
2023 Q3	$54	Hold	8	–	–	﹤0.01%	3394
2023 Q2	$63	Hold	8	–	–	﹤0.01%	3432
2023 Q1	$58	Hold	8	–	–	﹤0.01%	3357
2022 Q4	$0	Buy	+8	New	+$31	﹤0.01%	4106

Other funds holding CRBP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

NewEdge Advisors's CRBP Position: Q2 2026 in Review

NewEdge Advisors held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 8 shares worth $75. The position accounts for ﹤0.01% of the portfolio, ranked #4147.

NewEdge Advisors first reported a position in CRBP in Q4 2022 and has held it in 15 quarters since. The position peaked at $297K in Q2 2024. 66 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

NewEdge Advisors held 8 shares of Corbus Pharmaceuticals worth $75 as of Q2 2026.
NewEdge Advisors left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
Corbus Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #4147 holding.
NewEdge Advisors first reported a position in Corbus Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's Corbus Pharmaceuticals position peaked at $297K in Q2 2024.
66 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.